Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
N-terminal asparagine amidase pseudogene 1 (NTAN1P1) is a predicted noncoding pseudogene derived from the NTAN1 gene, which encodes N-terminal asparagine amidase, an enzyme involved in protein degradation through the N-end rule pathway[7]. NTAN1P1 does not encode a functional protein, and there are no established biological functions, disease associations, or known drug interactions for this pseudogene. Its similarity in name to NTAN1, a recognized enzyme, may cause confusion; however, NTAN1P1 is a pseudogene and not regarded as a drug target, receptor, transporter, or enzyme[7]. Essential clarification: - NTAN1P1 is easily confused with NTAN1 (N-terminal asparagine amidase), an enzyme with active biological function[2][4]. Only NTAN1 is a true protein target—NTAN1P1 is not. - There are no reports of NTAN1P1 acting as a miRNA decoy or regulating NTAN1 function, unlike well-studied pseudogenes such as PTENP1, KRASP1, or HMGA1-p[1][5]. - NTAN1P1’s status as a pseudogene means it is not considered a therapeutic target, and it is not involved in recognized molecular pathways or disease processes.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on N-terminal asparagine amidase pseudogene 1 (NTAN1P1).